Nexplanon Duration of Use
Nexplanon is FDA-approved to remain in place for up to 5 years, after which it must be removed and can be immediately replaced if continued contraception is desired. 1
FDA-Approved Duration
- The etonogestrel implant (Nexplanon) provides contraceptive protection for 5 years from the time of insertion, representing an updated approval from the previous 3-year duration. 1
- The implant must be removed by the end of the fifth year, though immediate replacement with a new implant is permitted at the time of removal without requiring backup contraception. 1, 2
Clinical Evidence Supporting 5-Year Use
- No pregnancies occurred during years 4 and 5 in the FDA clinical trial that enrolled 399 women who had been using Nexplanon for 36 months and continued for an additional 2 years (Pearl Index 0.0,95% CI 0.00-0.69). 1
- Etonogestrel serum concentrations remain well above the ovulation threshold throughout the 5-year period, with mean levels of 123 pg/mL at 4 years and 111 pg/mL at 5 years—both substantially above the 90 pg/mL threshold required to suppress ovulation. 1, 3
- Independent research corroborates these findings, with one study showing 100% efficacy through 5 years of use with no documented pregnancies during extended follow-up. 4
Contraceptive Efficacy Throughout Approved Duration
- Nexplanon demonstrates exceptional effectiveness with a failure rate of less than 0.05% during the entire 5-year approved period, making it one of the most effective reversible contraceptive methods available. 2, 1
- Both typical-use and perfect-use failure rates remain below 1% throughout all 5 years of use. 2, 1
- Real-world effectiveness data from the NORA study (7,364 users) confirmed a Pearl Index of 0.04 per 100 woman-years, consistent with clinical trial data. 5
Important Clinical Considerations
- Backup contraception is required for 7 days after initial insertion only when the implant is placed more than 5 days after the start of menstrual bleeding. 6, 1
- When inserted within the first 5 days of menstrual bleeding, immediate contraceptive protection is provided without backup methods. 6, 1
- The 84% continuation rate at 1 year reflects high user satisfaction despite common irregular bleeding patterns (22% amenorrhea, 34% infrequent spotting, 7% frequent bleeding, 18% prolonged bleeding). 2
Removal and Replacement
- At the 5-year mark, schedule removal of the implant; if continued contraception is desired, a new implant can be inserted immediately through the same incision without requiring backup contraception. 7, 1
- Return to fertility is rapid, with etonogestrel levels becoming undetectable within 1 week of removal and pregnancies documented as early as 7-14 days post-removal. 1
- Removal can be performed at any time during the menstrual cycle. 7
Special Populations
- For patients taking hepatic enzyme-inducing medications (efavirenz, nevirapine, or most protease inhibitors), contraceptive efficacy may be reduced, and alternative or additional contraceptive methods should be used. 2
- Women with BMI ≥30 kg/m² have relatively lower etonogestrel serum concentrations (ratio 0.76-0.88 compared to BMI <30), but concentrations remain effective with substantial overlap between BMI categories, and no pregnancies occurred in this population during the 5-year trial. 1